<DOC>
	<DOC>NCT02996682</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with chronic HCV infection and decompensated cirrhosis.</brief_summary>
	<brief_title>Efficacy and Safety of Sofosbuvir/Velpatasvir Â± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Key Chronic HCVinfected males and nonpregnant/nonlactating females Treatment naive or treatment experienced individuals ChildPughTurcotte Score 712 at screening Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Communicable Diseases</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Decompensated Cirrhosis</keyword>
</DOC>